Unexpected Favorable Outcome to Sintilimab Plus Bevacizumab in an EGFR-mutated Non-small Cell Lung Cancer Patient: A Case Report
Overview
Pulmonary Medicine
Affiliations
A 53-year-old man diagnosed with disease stage IIIB pulmonary adenocarcinoma underwent chemotherapy and radiotherapy in the first-line setting. After disease progression, he received targeted therapy because of subsequent detection of EGFR exon 19 del mutation. Following an increase in his adrenal metastases, a combination of immunotherapy and antiangiogenic therapy (sintilimab plus bevacizumab) was commenced. After one month, imaging showed that the adrenal metastases had shrunk and a progression-free survival (PFS) of 6.0 months was achieved. In this case, we showed that the PD1 inhibitor sintilimab plus bevacizumab was effective in a refactory advanced EGFR-mutant NSCLC with positive PD-L1 expression. KEY POINTS: Our case report provides clinical evidence of the durable response of a patient with advanced EGFR-mutant lung adenocarcinoma to a combination of immunotherapy and anti-angiogenic agent, sintilimab and bevacizumab, as subsequent-line therapy. Sintilimab and bevacizumab combination therapy was well-tolerated and effective, resulting in dramatic tumor reduction and improvement in clinical symptoms.
Wan C, Zhang Y, Liu P, Mei X, Cheng G, Pang J J Thorac Dis. 2023; 15(10):5648-5657.
PMID: 37969256 PMC: 10636450. DOI: 10.21037/jtd-23-1399.
[Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer with EGFR Mutation].
Zhu Y, Dai Z Zhongguo Fei Ai Za Zhi. 2022; 25(10):742-749.
PMID: 36167460 PMC: 9619349. DOI: 10.3779/j.issn.1009-3419.2022.101.44.
Ai Q, Chen W, Li Y, Li G Front Immunol. 2022; 13:840916.
PMID: 35720298 PMC: 9204206. DOI: 10.3389/fimmu.2022.840916.
Li Y, Zhou Y, Liu Y, Zhang G, Xiao L, Li N Thorac Cancer. 2021; 12(11):1780-1783.
PMID: 33949137 PMC: 8169295. DOI: 10.1111/1759-7714.13967.
Zhai C, Zhang X, Ren L, You L, Pan Q, Pan H Front Oncol. 2021; 10:619010.
PMID: 33680942 PMC: 7927598. DOI: 10.3389/fonc.2020.619010.